Clinical Case of VEXAS-Negative Recurrent Polychondritis Associated with Lymphoid Tumor
https://doi.org/10.20514/2226-6704-2025-15-5-383-390
EDN: SAPRFQ
Abstract
A clinical case of lymphoid tumor hiding under the «mask» of recurrent polychondritis with high activity of inflammatory process and limited response to treatment is presented. In addition to auricle damage, the disease was accompanied by non-erosive non-deforming arthritis, tenosynovitis of the Achilles tendon with its rupture, episcleritis, nasal chondritis, skin lesions in the form of Sweet neutrophilic dermatosis, ascending aorta dilation, subclinical signs of lung and pericardial damage, and development of macrocytic anemia with normal blood levels of vitamin B12 and folic acid, absence of laboratory manifestations of autoimmunity. Despite the fact that recurrent polychondritis with similar clinical and laboratory signs may be part of the phenotype of recently described adult autoinflammatory syndrome (VEXAS), the determination of its genetic marker gave a negative result.
Supporting agencies: The authors declare no funding for this study.
About the Authors
A. V. Yagoda
Stavropol State Medical University, Department of Hospital Therapy
Russian Federation
Russian Federation
Alexander V. Yagoda — Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy
Stavropol
P. V. Koroy
Stavropol State Medical University, Department of Hospital Therapy
Russian Federation
Russian Federation
Pavel V. Koroy — MD, PhD, Professor, Professor of Department of Hospital Therapy
Stavropol
D. P. Kharchenko
Stavropol Regional Clinical Hospital
Russian Federation
Russian Federation
Dina P. Kharchenko — Нead of the Rheumatology Department
Stavropol
N. N. Gladkikh
Stavropol State Medical University, Department of Hospital Therapy
Russian Federation
Russian Federation
Natalia N. Gladkikh — MD, PhD, Professor, Professor of Department of Hospital Therapy
Stavropol
I. P. Popova
Stavropol Regional Clinical Hospital
Russian Federation
Russian Federation
Inna P. Popova — Doctor of the Therapeutic Department
Stavropol
References
1. Mathew S.D., Battafarano D.F., Morris M.J. Relapsing polychondritis in the Department of Defense population and review of the literature. Semin. Arthritis Rheum. 2012;42(1):70-83. doi: 10.1016/j.semarthrit.2011.12.007
2. Hazra N., Dregan A., Charlton J. et al. Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study. Rheumatology (Oxford). 2015;54(12):2181-2187. doi: 10.1093/rheumatology/kev240
3. Mathian A., Miyara M., Cohen-Aubart F. Relapsing polychondritis: a 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best. Pract. Res. Clin. Rheumatol. 2016;30(2):316-333. doi: 10.1016/j.berh.2016.08/001
4. Denisov L.N., Vinogradova I.B., Bakhtina L.A. Recurrent polychondritis: a review of the literature and a clinical case description. Modern Rheumatology Journal. 2023;17(1):83-88 [In Russian]. doi: 10.14412/1996-7012-2023-1-83-88
5. Shimizu J., Yamano Y., Yudoh K., Suzuki N. Organ involvement pattern suggests subgroups within relapsing polychondritis: comment on the article by Dion et al. Arthritis Rheumatol. 2018;70(1):148-149. doi: 10.1002/art.40330.
6. Puechal X., Terrier B., Mouthon L. et al. Relapsing polychondritis. Joint Bone Spine. 2014;81(2):118-124. doi: 10.1016/j.jbspin.2014.01.001
7. Dion J., Costedoat-Chalumeau N., Sène D. et al. Relapsing polychondritis can be characterized by three different clinical phenotypes: analysis of a recent series of 142 patients. Arthritis Rheumatol. 2016;68(12):2992-3001. doi: 10.1002/art.39790
8. Yagoda A.V., Gladkikh N.N. Endocardium and heart valves in systemic rheumatic diseases. Stavropol. 2021; 384 p. [In Russian].
9. Buckner J.H., Wu J.J., Reife R.A. et al. Autoreactivity against matrilin-1 in a patient with relapsing polychondritis. Arthritis Rheum. 2000;43(4):939-943. doi: 10.1002/1529-0131(200004) 43:43.0.CO;2-Z
10. Cynthia M. Magro, Molly Dyrsen. Angiocentric lesions of the head and neck. Head Neck Pathol. 2008;2(2):116-130. doi: 10.1007/s12105-008-0049-2
11. Suyama Y., Ishimoto S.-I., Hagiwara K. Clinical images: arytenoid chondritis. Arthritis Rheumatol. 2017;69(6):1193. doi: 10.1002/art.40088
12. McAdam L.P., O’Hanlan M.A., Bluestone R., Pearson C.M. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976;55(3):193-215. PMID:775252
13. Chernyak V.I., Savel’ev A.I., Pogromov A.P. et al. Relapsing holychondritis. Clinical Medicine (Russian Journal). 2014;86(11):22-28 [In Russian].
14. Hebbar M., Brouillard M., Wattel E. et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia. 1995;9(4):731-733. PMID: 7723411
15. Yanagi Т., Matsumura T., Kamekura R. et al. Relapsing poly chondritis and malignant lymphoma: is polychondritis paraneoplastic? Arch. Dermatol. 2007;143(1):89-90. doi: 10.1001/archderm.143.1.89
16. Horváth A., Páll N., Molnár K. et al. A nationwide study of the epidemiology of relapsing polychondritis. Clin. Epidemiol. 2016;8:211- 230. doi: 10.2147/CLEP.S91439
17. Cohen P.R. Paraneoplastic relapsing polychondritis. Arch. Dermatol. 2007;143(7):949-950. doi: 10.1001/archderm.143.7.949
18. Mekinian A., Grignano E., Braun T. et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016;55(2):291-300. doi: 10.1093/rheumatology/kev294
19. Michet C.J., McKenna C.H., Luthra H.S., O’Fallon W.M. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann. Intern. Med. 1986;104(1):74-78. doi: 10.7326/0003-4819-104-1-74
20. Terao C., Yoshifuji H., YamanoY. et al. Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases. Rheumatology (Oxford). 2016;55(9):1686-1692. doi: 10.1093/rheumatology/kew233
21. Foidart J.M., Abe S., Martin G.R. et al. Antibodies to type II collagen in relapsing polyhondritis. N. Engl. J. Med. 1978;229(22):1203-1207. doi: 10.1056/NEJM197811302992202
22. Beck D.B., Ferrada M.A., Sikora K.A. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl. J. Med. 2020;383(27):2628-2638. doi: 10.1056/NEJMoa2026834
23. Ferrada M.A., Sikora K.A., Luo Y. et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol. 2021;73(10):1886-1895. doi: 10.1002/art.41743
24. Tsuchida N., Kunishita Y., Uchiyama Y. et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann. Rheum. Dis. 2021;80(8):1057-1061. doi: 10.1136/annrheumdis-2021-220089
25. Chaltsev B.D., Torgashina A.V., Lila A.M. et al. VEXAS syndrome: on the threshold of changing perceptions of known diseases. Modern Rheumatology Journal. 2023;17(6):92-101 [In Russian]. doi: 10.14412/1996-702-2023-6-92-101
26. Guseva N.G. Problem of rheumatic and oncological diseases association (pathogenetic and clinical aspects). Rheumatology Science and Practice. 2004;42(4):60-67 [In Russian].
27. Marcoval J., Martin-Callizo C., Valenti-Medina F. et al. Sweet syndrome: long-term follow-up of 138 patients. Clin. Exp. Dermatol. 2016;41(7):741-746. doi: 10.1111/ced.12899
28. Gurnari C., Mannion P., Pandit I. et al. UBA1 screening in Sweet syndrome with hematological neoplasms reveals a novel association between VEXAS and chronic myelomonocytic leukemia. Hemasphere. 2022;6(10):e775. doi: 10.1097/HS9.0000000000000775
29. Sterling D., Duncan M.E., Philippidou M. et al. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist. J. Am. Acad. Dermatol. 2023;89(6):1209-1214. doi: 10.1016/j.jaad.2022.01.042
30. Obiorah I.E., Patel B.A., Groarke E.M., et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 2021;5(16):3203-3215. doi: 10.1182/bloodadvances.2021004976
31. Ferrada M.A., Savic S., Cardona D.O. et al. Translation of cytoplastic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022;140(13):1496-1506. doi: 10.1182/blood.2022016985
32. Temple M., Kosmider O. VEXAS syndrome: a novelty in MDS landscape. Diagnostics (Basel). 2022;12(7):1590. doi: 10.3390/diagnostics12071590
33. Khitri M.-Y., Guedon A.F., Georgin-Lavialle S. et al. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open. 2022; 8:e002255. doi: 10.1136/rmdopen-2022-002255
Review
For citations:
Yagoda A.V., Koroy P.V., Kharchenko D.P., Gladkikh N.N., Popova I.P. Clinical Case of VEXAS-Negative Recurrent Polychondritis Associated with Lymphoid Tumor. The Russian Archives of Internal Medicine. 2025;15(5):383-390. (In Russ.) https://doi.org/10.20514/2226-6704-2025-15-5-383-390. EDN: SAPRFQ
Views:
20
Email this article 